Novo Nordisk's Q2 brand detail: Ozempic DKK 31.4 billion, Wegovy injection flat, Wegovy pill DKK 3.2 billion

Novo Nordisk reported second-quarter 2026 results on August 4, and the brand-level detail tells a clearer story than the headline numbers: Ozempic sales rose 3% to DKK 31.375 billion, the Wegovy injection grew just 1% to DKK 19.484 billion, and the Wegovy pill brought in DKK 3.218 billion in its second full quarter on the market ^[1].

Across the whole company, adjusted sales were DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit was DKK 33,389 million, up 11% at constant exchange rates ^[2]. Those adjusted figures exclude a one-time benefit from provision reversals tied to the 340B Drug Pricing Program in the US, and the profit figure excludes DKK 6.3 billion in non-recurring, non-cash impairment charges on pipeline assets, including DKK 4.0 billion related to monlunabant ^[2].

Novo also raised its full-year 2026 outlook. The company now expects adjusted sales growth of 0% to -6% at constant exchange rates and adjusted operating profit growth of 0% to -6%, up from the -4% to -12% ranges it gave on May 6, 2026 ^[2]. Novo said the improvement is "driven by increased expectations for GLP-1 product sales" ^[2]. On a non-adjusted basis, the company said the midpoints of its 2026 sales and operating profit growth guidance would be 5% and 12% ^[2]. Even so, Benzinga reported that sales fell against a tough year-earlier comparison and that the stock dropped on the news ^[1].

What the brand split shows

All three products are semaglutide. Ozempic is the injection approved for type 2 diabetes, Wegovy is the injection for weight management, and the Wegovy pill is the oral form of the same molecule.

The growth rates are the part worth noticing. A 1% increase for Wegovy injection is close to flat, while the pill went from nothing to DKK 3.218 billion in about six months of selling ^[1]. In other words, the newer oral option — not the long-established injection — is supplying most of the franchise's momentum right now.

The sources provided do not break out how much of each product's sales came from the US versus other countries, how many US patients are filling prescriptions, or how much of the pill's revenue came from cash-pay channels versus insurance. Those details are not yet known from this material.

Why it matters for patients

Sales mix influences what a manufacturer pushes hardest: which product gets supply priority, which gets promotional and discount support, and which shows up first in pharmacy and telehealth channels. A pill that is growing while the injection stalls gives Novo a reason to keep investing behind the oral option.

It also matters for competition. Novo's guidance increase was attributed specifically to higher expected GLP-1 sales ^[2], which suggests the company sees continued demand despite rivals in the obesity market. Steady or rising competition among semaglutide, tirzepatide (Mounjaro and Zepbound) and oral entrants like orforglipron (Foundayo) has historically been the main pressure on list prices and cash-pay offers, though none of the sources here quantify current US pricing.

Finally, the flat Wegovy injection number is a reminder that headline demand for weight-loss shots is no longer growing at the pace it once did. What that means for insurance coverage decisions in 2027 is not addressed in these sources.

What happens next

• August 4, 2026: Novo published its full financial results for the first six months of 2026, alongside the adjusted sales and profit announcement and raised outlook ^[2].
• August 5, 2026: The company held an investor conference call at 13.00 CEST, or 7:00 a.m. EDT, where management typically takes analyst questions on product-level trends ^[2].

Novo's 2026 outlook assumptions rest on the ones described in its first-quarter financial report, which the company flagged as still applying ^[2]. Any change would most likely surface at the next quarterly update.